BioStem Technologies, Inc. balance sheet BSEM

As of Jun 30, 2026, BioStem Technologies, Inc. had total assets of $48.8 million and total liabilities of $21.2 million. Stockholders' equity was $27.6 million. It held $7.0 million in cash and investments against $223,826 of total debt, net cash of $6.7 million. The current ratio, current assets divided by current liabilities, was 0.98.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
Assets
Cash
7
Cash and investments
7
Receivables
7
Inventory
5
Total current assets
21
Property and equipment, net
4
Goodwill
2
Total assets
49
Liabilities and equity
Total current liabilities
21
Total liabilities
21
Stockholders' equity
28
Debt
Long-term debt
0
Lease liabilities
0
Total debt
0
Net cash
7
Ratios
Current ratio
0.98x
Debt to equity
0.01x
Book value per share
1.55
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BSEM (Nasdaq)
Fiscal year ends
December 31
Incorporated in
FL
Headquarters
Pompano Beach, FL
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1658678
Former names
BIOSTEM TECHNOLOGIES (until Oct 28, 2025)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.